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Abstract The presenilin 1 (PSI) gene located on chromosome 
14 has been linked with the majority of early-onset FAD. The 
normal biological role of PS1 as well as the mechanism by which 
mutations in PSI cause FAD remains unknown. PSI expression 
in platelets and the Dami megakaryocytic cell line was examined 
by Western blot analysis and RT-PCR. Using an anti-N- 
terminus PS1 antibody we detected PSI immunoreactive bands 
of 44, 32 and 27 kDa in both cell types. After RT-PCR we 
observed that platelets and megakaryocytes carry at least four 
different PSI transcripts. One of them is a novel PSI splice 
variant that lacks the coding sequence for exon 10 resulting in a 
shorter 409 amino acid protein. 
Key words: Alzheimer's disease; Presenilin; mRNA; Gene 
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1. Introduction 
Alzheimer's disease is characterized pathologically by neu- 
ronal loss, glial proliferation and the deposition of amyloid in 
the form of senile or neuritic plaques, congophilic angiopathy 
and intraneural neurofibrillary tangles [1]. Amyloid fibrils in 
senile plaques and in cerebral vessels walls in AD are com- 
posed of a protein named amyloid [3 (A[3), which is a fragment 
(39-44 residues) derived from the larger amyloid precursor 
protein [3PP. When the [3PP molecule is cleaved at different 
sites in the extracellular and transmembrane domains it gen- 
erates soluble A[~ (sA[~). sA[~ has been found in circulation in 
biological fluids and in the supernatant of cell cultures and it 
has been postulated to be the source of plaque amyloid in AD 
[2 5]. 
Missense mutations within or close to the AI3 region in the 
[3PP gene localized in chromosome 21 have been found linked 
with some forms of FAD and hereditary cerebral hemorrhage 
with amyloidosis-Dutch type (HCHWA-D) [1], and current 
studies indicate that the polymorphism of the apo E gene 
(E4) on chromosome 19 is a genetic risk factor for familial 
and sporadic late onset AD. Recently, Sherrington and col- 
leagues [6] have reported the cloning of a novel gene termed 
S182 or presenilin 1 (PSI) bearing missense mutations [6,7] 
associated with segregating early-onset FAD linked to chro- 
mosome 14. A number of mutations in PS1 have been all 
found associated with early-onset FAD (for review see [8]). 
In addition, two mutations were described in a similar gene 
(67% homologous to PS1), named STM-2, E5-1 or PS2 lo- 
cated on chromosome l [9,10]. The predicted amino acid se- 
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quence encoded in the longest open reading frame composed 
of 10 exons [7] reveals high similarities with the Caernorhab- 
ditis elegans protein SEL-12 [11]. SEL-12 facilitates LIN-12 
mediated cell signalling via the Notch family of receptors 
during development of C elegans. Protein homology has 
also been found with the C. elegans sperm integral membrane 
protein SPE-4, a membrane protein active in spermatogenesis 
as well as with the mammalian chromogranin A and the c~- 
subunit of mammalian voltage-dependent calcium channel [6]. 
The primary structure of PSI resembles that of an integral 
membrane protein such as a receptor, a channel protein or 
a structural membrane protein although its physiological 
function and role in AD pathogenesis are not known. 
The expression of PSI is not limited to neural tissue. Hy- 
bridization of the PSI clone to northern blots detected two 
transcripts of approx. 3.0 and 7.0 kbp. Northern analysis, in 
situ hybridization, and immunohistochemical studies showed 
that presenilins are expressed in most regions of the brain and 
several peripheral tissues [6,12-15]. Different transcripts de- 
rived by alternative splicing of the PSI gene have been de- 
scribed in brain, fibroblasts and leukocytes [7,10,16,17]. The 
analysis of the expression of the presenilins is an important 
step in the understanding of the physiological function and 
the role of these proteins in AD. Herein, we report the finding 
of PSI transcripts in platelets and a megakaryocytic cell line 
by RT-PCR and Western blot analysis using a polyclonal 
anti-N-terminus PSI antibody. A novel PS1 isoform found 
in platelets and megakaryocytes is also described. 
2. Materials and methods 
2.1. Cell culture and platelet preparation 
The Dami megakaryocytic cell line (ATCC no. CRL-9792) was 
grown in Iscove's modified Dulbecco's minimal essential media sup- 
plemented with 10% horse serum, 50 gg/ml of gentamicin, 100 units/ 
ml of penicillin, 100 gg/ml of streptomycin, and 0.58 mg/ml of L- 
glutamine and maintained at 37°C in a 5% CO2/95% air atmosphere. 
Cells in the log phase of growth were washed twice in PBS, pelleted, 
and processed either for isolation of cellular RNA or Western blotting 
analysis. Human platelets were isolated from whole blood as de- 
scribed [18]. Briefly, 40 ml of venous blood were collected and anti- 
coagulated by sodium heparin solution. Blood was sedimented by 
centrifugation and the resultant platelet-rich plasma was collected. 
By differential centrifugation, platelets were harvested and washed 
three more times in 100 mmol/l NaCI, 8.5 mmol/1 Tris, 8.5 mmol/l 
glucose, and 1 mmol/l Na2EDTA, pH 7.4. The final platelet pellet was 
used for RNA isolation and Western blot analysis. 
2.2. RNA isolation and reverse transcription-polymerase chain reaction 
(RT-PCR) 
Total cellular RNAs were isolated by the guanidine isothiocyanate 
method using Trizol LS (Gibco BRL) reagent. Reverse transcription 
of RNA (1 gg) extracted from cell line and platelets was performed 
with the first strand cDNA synthesis kit (Boehringer Mannheim) 
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using the avian myeloblastosis virus (AMV) reverse transcriptase with 
the downstream primer 01R specific for PSI (Table 1). PCR amplifi- 
cation of the first strand cDNA produced by reverse transcription was 
performed by introducing the upstream amplimer 01F in 1XPCR 
buffer (Perkin Elmer). Each PCR cycle consisting of a denaturation 
step (940C, 1 min), an annealing step (40°C, 2 min), and an elongation 
step (72°C, 3 min) was repeated 30 times. For controls, RNA samples 
were pretreated with RNase A for 30 rain at 37°C and subjected to 
RT-PCR; in these controls, no specific amplification was observed. 
2.3. PCR amplification and DNA sequencing 
10 ktl of the products of the PS1 reaction were reamplified using 
oligonucleotide primers 02F and 02R for 30 cycles of 94°C for 1 rain, 
45°C for 1 min and, 72°C for 2 min The resulting PCR product was 
then digested with XmnI (New England BioLabs) and DraI (Gibco, 
BRL) following the manufacturer's conditions. In a different reaction, 
10 ~tl of the PSI cDNA were reamplified using oligonucleotides for- 
ward 05F and reverse O5R under the same conditions. After success- 
ful reamplification, the resulting PCR product was subcloned into the 
pCRII vector (TA cloning kit, Invitrogen). Recombinant plasmid 
DNA was isolated from seven clones and sequenced by the dideoxy 
chain termination method in both directions. To ensure specific am- 
plification of platelet's RNA, RT-PCR reactions were performed 
using a set of oligonucleotide primers for the non-polymorphic do- 
main of the beta chain gene of class II HLA-DR molecule (which is 
found predominantly on the surface of activated T-cells, B-cells, and 
antigen-presenting cells) [19] and in a different reaction, the same 
platelet's RNA was used in RT-PCR with synthetic oligonucleotides 
based on the sequence of the platelet membrane glycoprotein lib 
(GPIIb) [20] as described by Gardella et al. [21]. PCR amplification 
using oligonucleotides 03F and 03R, was performed for 25 cycles of 
30 s at 94°C, 30 s at 52°C, and 40 s at 72°C. Amplification products 
were resolved on 4% Methaphor (FMC) gel and visualized by ethi- 
dium bromide staining. Reamplification f PSI cDNA was also per- 
formed with oligonucleotides 04F and 04R. PCR conditions of 94°C 
for 40 s, 45°C for 40 s and, 72°C for 1 min were repeated 30 times. 
PCR products were separated on 5% polyacrylamide g ls, visualized 
by ethidium bromide staining and subcloned into the pCRII vector. 
Recombinant plasmid DNA was isolated from 10 clones and se- 
quenced in both directions. 
2.4. Western blotting of cell extracts 
A peptide ncompassing residues 48-70 of the PS1 molecule [6] was 
used to raise an anti-PSI polyclonal antibody (PSI (N48-70)). This 
antibody was produced by custom order at Research Genetics (Hunts- 
ville, AL). The serum was affinity purified using a CNBr-activated 
Sepharose column (Pharmacia, LKB) on which the HPLC purified 
synthetic peptide was coupled following the manufacturer's in truc- 
tions. Isolated platelets and megakaryocytes were triturated in RIPA 
buffer (50 mM Tris-HC1 pH 8.0, 150 mM NaC1, 5 mM EDTA, 1% 
Triton X-100, 0.5% cholic acid, and 0.1% SDS) with protease inhibi- 
tors (complete, 1ktg/ml leupeptin, 0.1 ~tg/ml pepstatin, and 1 ~tg/ml L- 
1-chloro-3-[4-tosylamido]-7-amino-2-heptanone-HC1, all from Boeh- 
ringer Mannheim) and cells extracts were analyzed in 16% Tris-Tri- 
cine SDS-PAGE, following by Western blotting with affinity purified 
PSI(N48-70) antibody (1 :I00). Controls included the use of pre-im- 
mune serum and pre-absorption of the purified antibody with the 
synthetic N48-70 peptide. 
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3. Results 
We amplified PS1 cDNA by RT-PCR from platelets and 
the Dami megakaryocytic cell line using oligonucleotide pri- 
mers 01F and 01R. The resulting PCR product contained full- 
length PSI cDNA (1885 bp) (not shown). After amplification, 
PCR products were characterized by polyacrylamide gel elec- 
trophoresis. Besides noting it expected size, reamplified frag- 
ments using oligonucleotides 02F and 02R (573 bp) (Fig. 1A, 
lane 2) were digested with XmnI and DraI restriction enzymes 
(Fig. 1A, lanes 3,4, respectively). The resulting DNA frag- 
ments correspond exactly to the predicted size of these restric- 
tion enzyme-digested fragments (132 and 441 bp for XmnI and 
204 and 369 bp for DraI). PSI cDNA reamplified using oli- 
gonucleotides 05F and O5R (651 bp) was subcloned and se- 
quenced in both directions. The complete sequence of the 
subcloned cDNA fragments howed 100% identity to that of 
the PSI molecule (GenBank accession o. L42110 and [22]). 
To ensure specific amplification of platelet's RNA, RT-PCR 
reactions were performed using oligonucleotide primers spe- 
cific either for the class II HLA-DR molecule (which is found 
predominantly on the surface of activated T-cells, B-cells, and 
antigen presenting cells) or for the platelet membrane glyco- 
protein l ib molecule (GPIIb). PCR amplification of platelet's 
RNA for HLA-DR was negative (even after a second round 
of reamplification). On the other hand, RT-PCR for platelet's 
GPI Ib produces an expected fragment of 809 bp (Fig. 1B, lane 
2) establishing the uncontaminated nature of the RNA used in 
these experiments [21]. Similarly, RNA isolated from the 
Dami megakaryocytic cell line produced a strong signal for 
GPI Ib (Fig. IB, lane 3) and was negative for HLA-DR. RT- 
PCR using megakaryocyte's RNA and PSI oligonucleotides 
primers 02F and 02R in the same manner described for plate- 
let's RNA gave a PCR product of 573 bp (Fig. 1 B, lane 4) 
that was then digested with XmnI and DraI as described be- 
fore (Fig. 1B, lanes 5,6, respectively). 
Alternative splicing of exon 3 [7] was analyzed using oligo- 
nucleotides 03F and 03R. After reamplification, PCR prod- 
ucts from platelets and megakaryocytes were resolved on 4% 
metaphor agarose showing two bands of 146 and 134 bp 
(Fig. 2A, lanes 2,3). The difference of 12 bp is due to 
alternative splicing of the sequence VRSQ (codons 26-29) 
(Fig. 2B). A similar pattern of expression was observed in 
platelets, the Dami megakaryocytic cell line and two neuro- 
blastoma cell lines NTera-2/cL.D1 and SH-SY5Y (Fig. 2A, 
lanes 4,5). After PCR amplification of PSI cDNAs with oli- 
gonucleotides 04F and 04R a PCR product of 584 bp repre- 
senting full-length PSI was found to constitute the majority of 
Table 1 
Sequence and position of oligonucleotide primers 
Primer Sequence Exon 
01F 
01R 
02F 
02R 
03F 
03R 
04F 
04R 
05F 
05R 
5'-ATC GGG ATC CTC ACA TCG GAA ACA AAA CAG-Y 2 
5'-CTA AGC GGC CGC ACC TCG TCC CTC AAA TCT-3' 12 
5'-GAG CAA GAT GAG GAA GAA GAT-3' 4 
5'-TGA AAT CAC AGC CAA GAT GAG-Y 7 
5'-GAC AAC CAC CTG AGC AAT-Y 3 
5'-CTC ATC TTG CTC CAC CAC CTG-3' 4 
5'-ATC TCC GGC AGG CAT ATC T-3' 7 
5'-ATA ATC TAG AAC TAT ATG GCT ACG AA-Y I 1 
5'-GAT TTA GTG GCT GTT TTG TG-3' 8 
5'-ATC AGC GGC CGC TAA CCG CAA ATA TGC-Y 12 
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the amplified material in platelets (Fig. 3A, lane 2) and mega- 
karyocytes (not shown). Amplification of PS1 cDNA from 
neuroblastoma cell lines produced a similar signal (Fig. 3A, 
lanes 5,6). Alternative splicing of exon 8 (codons 257-289) 
previously reported in leukocytes [10] was observed to consti- 
tute a very small percentage of PSI transcripts in platelets and 
the Dami cell line. After reamplification of PS1 cDNA using 
oligonucleotides primers (04F and 04R) we observed a faint 
band of 485 bp in polyacrylamide g ls. This band was cut out 
the gel and reamplified under the same conditions (Fig. 3A, 
lane 3). After cloning, this PCR product was identified by 
DNA sequencing as the alternative splicing PS1 form lacking 
exon 8 (99 bp) (Fig. 3B). Another faint band of lower size 
(410 bp) present in amplification products from platelets and 
megakaryocytes was cut out from the gel and reamplified as 
described before (Fig. 3A, lane 4). Sequence analysis revealed 
that this amplified PCR product represents a novel alternative 
splicing form of PS1, lacking exon 10 (174 bp). As a result, 
exon 10 (codons 319-376) is spliced out, without altering the 
reading frame of the rest of the PS1 molecule (Fig. 3C). 
We prepared a specific anti-N-terminus antiserum against a 
synthetic peptide (N48-70) derived from the protein sequence 
of the PS1 molecule. Serum antibodies were affinity purified 
against he peptide and used in Western blot experiments. The 
predicted molecular mass of PS1 is ,-~ 52 kDa, but it has been 
recently reported that in vitro translated PSI migrates as a 
protein of ,-,43 kDa in SDS-polyacrylamide g ls [16]. A ,~ 50 
kDa band can be seen in megakaryocytes and platelets with 
an intensity dependent on the boiling time in loading buffer 
previous to electrophoresis. Higher molecular mass bands of 
--,80 and 100 kDa can also be detected as a function of 
boiling time as has previously been described [16]. Our N- 
terminus antibody also recognized a protein of 44 kDa in 
platelets and megakaryocytes (Fig. 4) and in neuroblastoma 
cell lines (data not shown). Staining was abolished when the 
antibody was pre-incubated with the synthetic peptide. Two 
lower molecular mass bands of ,~ 27 and 32 kDa can also be 
seen in both cell types (Fig. 4, lanes 1,2) and in neuroblastoma 
cell lines (not shown). 
1 
A 
I 
i 
2 3 4 5 6 bp 
Fig. 1. Ethidium bromide stained 5% polyacrylamide g l (PAGE). 
(A) 573 bp PCR product of amplification from platelets (lane 2) 
and restriction enzyme analysis of the same fragment. XmnI (lane 3) 
digestion results in fragments of 132 and 441 bp. DraI digestion 
(lane 4) produces fragments of 204 and 369 bp. Lane 1 : BioMarker 
Low (Bio Ventures, Inc.) molecular weight marker. (B) RT-PCR 
products (809 bp) of amplification of platelets (lane 2) and mega- 
karyocytes (lane 3) RNA for GPIIb. Reamplification of PSI cDNA 
from megakaryocytes results in a band of 573 bp (lane 4). Restric- 
tion enzyme analysis results in the same pattern described in (A) for 
XmnI (lane 5) and DraI (lane 6). Lane 1: BioMarker Low. 
A 
146 bp ÷ VRSQ 
134 bp -VRSQ 
B 
EXON 3 EXON 4 
AAT ACT GTA CGT AGC CAGgtac....atagAAT GAC AAT 
N T V R S Q N D N 
Fig. 2. (A) PCR amplification of PSI cDNA from platelets (lane 2), 
megakaryocytes (lane 3), NT2 cells (lane 4), and SHSY5Y (lane 5) 
cell line shows amplified fragments of 134 and 146 bp. Lane 1: Bio- 
Marker Low. (B) Intrordexon structure of alternatively spliced exon 
3 [7]. The predicted amino acids are positioned below the nucleotide 
sequence in the middle of their respective codons. Exons are in capi- 
tals while the flanking introns are in lower-case l tters. 
4. Discussion 
Platelets are responsible for up to 90% of the anti-AI] im- 
munoreactivity in whole blood [23], representing a probable 
source of sA~. After the discovery by linkage analysis of the 
relationship between the majority of the cases of early-onset 
FAD and the PSI gene [6] we decided to investigate whether 
platelets also express PSI protein. 
We found evidence of PSI transcription in both platelets 
and megakaryocytes by specific RT-PCR. Although full- 
length PSI represents he major transcript, we identified other 
PCR products. We observed in platelets and megakaryocytes 
the presence of alternative splicing of exon 3 as described by 
Clark et al. [7]. The importance of these isoforms should be 
considered since the sequence VRSQ (VRXQ motif) may be 
part of two potential phosphorylation sites for casein kinase 
II and protein kinase C in the PSI molecule [7]. Both isoforms 
are present in almost equimolecular amounts in platelets, 
megakaryocytes and neural cell lines whereas brain and lym- 
phoblasts have a different pattern with the shorter isoform 
representing more than 60% ([24] and unpublished observa- 
tion). A shorter mRNA derived by alternative splicing of exon 
8 (codons 257-289) is present in low amounts in both platelets 
and megakaryocytes. This represents an isoform of 434 amino 
acids that has been reported to be more prominent in leuko- 
cytes than in brain [10]. Exon 8 contains a hot-spot for PSI 
mutations with exons 5 and 8 together accounting for approx. 
65% of all PSI mutations reported so far. We also found a 
novel splice variant that splices out exon 10 (174 bp). The 
translated polypeptide lacks the sequence between codons 
319 and 373 of the full-length PSI that forms part of the 
acidic hydrophilic loop between the predicted transmembrane 
domains VI and VII [6]. So far, no mutations have been 
reported in this exon, but another isoform has been described 
where the insertion of an additional exon (92 bp) after exon 9 
results in a frame shift with a stop codon that generates a PS 1 
protein (I-374) of 374 amino acids [16]. In our case, the alter- 
native splicing phenomenon of exon 10 does not alter the 
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reading frame, producing a shorter isoform of 409 amino 
acids. Another splice variant hat lacks exon 10 and part of 
exon 11 (involving part of the predicted loop and the trans- 
membrane domain VII) and codon 321 changes from glutamic 
to aspartic acid was recently described as a member of a 
number of different PSI isoforms [17]. 
The Western blotting data using our polyclonal anti-N-ter- 
minus antibody shows a band of 44 kDa that can be detected 
in platelets and megakaryocytes (also seen in neuroblastoma 
cell lines), indicating that the PS1 gene product is expressed 
not exclusively in cell of neural origin. Beside full-length PSI, 
we observed immunoreactive bands of lower molecular weight 
representing proteolytic fragments or the presence of shorter 
isoforms of PSI. We found an immunoreactive band of -,, 32 
kDa that corresponds approximately to the molecular mass 
described for 1-374 by Sahara et al. [16]. A lower molecular 
mass band observed at ,~ 27 kDa suggests proteolytic leav- 
age. Interestingly, we have found an immunoreactive band of 
approximately the same molecular mass (,-, 27 kDa) that is 
labeled by our anti-N-terminus PSI antibody present in both 
normal and AD cerebrospinal fluid as well as a C-terminal 
immunoreactive band of ,-, 17 kDa in brain tissue [25]. The 
biochemical characterization f these molecules i currently in 
progress. 
A 
B 
EXON 7 EXON g 
TCA GTA TAT Ql~m......ae, l j~ ACA ATG 
G V Y ~ $  T M 
C 1 ;GG C1 G;GA I T1CAG 1 A TA IOCAACA A TGG I G11GG1 TGGGIG A 
I~0 2o¢ ~10 ~o 
C 
EXON 9 EXON 11 
• aT aeA OAA,~t~.._n,~pa OaA aTA 
N A E V R  G V 
AA~ ;C  C~;~ GT;A~A A1 GCAOA AAGGGGAN1 AAAACl  1G4~GA I 1GGGA 
Fig. 3. 5% polyacrylamide g l showing products of amplification 
(A) from platelets representing full length (lane 2), alternative splic- 
ing of exon 8 (lane 3), and exon 10 (lane 4). Lanes 5 and 6 show 
the results of amplification i  the same conditions for NTera-2/ 
cL.DI and SH-SY5Y cell lines, respectively. Lane 1:123 bp DNA 
marker (Gibco, BRL). DNA sequence analysis indicates that exon 7 
was spliced to exon 9 (B) and that exon 10 was spliced out (C). 
Fig. 4. Western blot of cell extracts run on 16% Tris-Tricine SDS- 
PAGE from megakaryocytes (lane 1) and platelets (lane 2). After 
blocking overnight with 5% non-fat dry milk in PBS-T, primary 
antibody (PS1 (N48-70)) was added diluted 1:100 in PBS-T and in- 
cubated for 2 h at room temperature. Secondary antibody was per- 
oxidase-conjugated anti-IgG (Dako) diluted 1:5000. Fluorograms 
were prepared with an ECL Western blotting kit (Amersham) ac- 
cording to the manufacter's specifications. 
PS1 has been linked to most of the cases of early-onset 
FAD and has also been reported to be present in senile 
plaques of sporadic and chromosome 14 linked AD cases 
[26] as well as in cerebrovascular AI3 deposits of AD patients 
[25]. The present study provides direct evidence that platelets 
have transcripts that encode the PSI protein. Furthermore, 
examination of the Dami megakaryocytic cell line reveals 
that these cells also have PSI mRNA and express PSI protein, 
indicating that PSI transcription occurs in ceils of the throm- 
bocytic lineage. So far, the expression profile of PSI and 13PP 
seems to be similar, with both genes being ubiquitously ex- 
pressed in neural and non-neural tissues. Additional experi- 
ments will be necessary to determine the function of PSI and 
its relationship to I]PP and how PSI is involved in the patho- 
genesis of AD. 
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